Scarica l'app Stockscreener
628.67
0.69%
-5.945
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$634.62
Aprire:
$634.8
Volume 24 ore:
253.81K
Relative Volume:
0.34
Capitalizzazione di mercato:
$65.93B
Reddito:
$14.92B
Utile/perdita netta:
$4.42B
Rapporto P/E:
15.32
EPS:
41.0422
Flusso di cassa netto:
$3.79B
1 W Prestazione:
-3.00%
1M Prestazione:
-15.34%
6M Prestazione:
-19.67%
1 anno Prestazione:
+4.47%
Intervallo 1D:
$625.00
$638.06
Intervallo di 1 settimana:
$625.00
$650.32
Portata 52W:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
628.84 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
440.37 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
828.64 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.63 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
152.60 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Ripresa | Piper Sandler | Overweight |
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Notice to Long-Term Shareholders of Commvault Systems, Inc. - GlobeNewswire
Allstate Corp Has $5.92 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Strong Cash Yield: Is Regeneron Pharmaceuticals Stock A Buy? - Trefis
Regeneron to create hundreds of jobs with new Hyderabad GCC - HR Katha
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
How Low Can REGN Really Go In A Market Crash? - Trefis
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing - The Motley Fool
U.S. biotech giant Regeneron chooses Hyderabad to set up GCC - The Hindu
Canaccord Cuts PT on Regeneron Pharmaceuticals (REGN), Cites a Disappointing Event - Insider Monkey
Important Notice to Long-Term Shareholders of Molina - GlobeNewswire
US biotech giant Regeneron to set up its first Global Capability Centre outside America in Hyderabad - NewsMeter
Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink? - Yahoo Finance
Regeneron Pharmaceuticals to set up Global Capability Centre (GCC) in Hyderabad - Telangana Today
Legal & General Group Plc Sells 27,332 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
US biotech major Regeneron identifies site for its GCC to be operational in 2nd half of 2026 in Hyderabad - Pharmabiz.com
Prospera Financial Services Inc Decreases Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Jefferies Financial Group Inc. Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
US Biotech Regeneron to launch Global Capability Centre in Hyderabad - BioSpectrum India
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Trial Wins And New Research Partnership - simplywall.st
US biotech Regeneron to launch global capability centre in India's Hyderabadstatement - marketscreener.com
Regeneron (REGN) Enters $2.32B Collaboration With Parabilis to Target ‘Undruggable’ Proteins - Yahoo Finance
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) - marketscreener.com
5 Cheap NASDAQ Stocks to Buy Right Now - Insider Monkey
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Simplify Asset Management Inc. - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN): Analyst Ratings Signal Strong Buy with 30% Upside Potential - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire about Securities Investigation - ACCESS Newswire
The week in pharma: action, reaction and insight – week to May 22, 2026 - The Pharma Letter
Why Regeneron (REGN) Is Down 8.5% After Melanoma Trial Miss and New Legal ScrutinyAnd What's Next - simplywall.st
Swedbank AB Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by LSV Asset Management - MarketBeat
Regeneron R&D Updates Test Market View On Long Term Pipeline Value - Yahoo Finance
Stocks making big moves this week: Toll Brothers, Booz Allen Hamilton, Strategy, Regeneron, and Micron - Yahoo Finance
ABN Amro Investment Solutions Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Lynozyfic AL Amyloidosis Data Gives Regeneron Pipeline And Valuation Focus - simplywall.st
Regeneron (REGN) Advances Gene Therapy Review in Europe - GuruFocus
Licensable picture: The exterior of Regeneron Pharmaceuticals May 22, 2026 in Tarrytown. - Reuters Connect
Parabilis Medicines Starts IPO On Promising Cancer Therapy Trials (PBLS) - Seeking Alpha
Regeneron Says Otarmeni Application Accepted Under EU Accelerated Assessment - Moomoo
EMA accepts Regeneron’s gene therapy for rare hearing loss By Investing.com - Investing.com Canada
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss - The Manila Times
Rx Rundown: Parabilis Medicines, Boston Scientific, Amgen and more - Medical Marketing and Media
REGN News | REGENERON PHARMACEUTICALS (NASDAQ:REGN) - ChartMill
(REGN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc.REGN - PR Newswire
Regeneron reports positive trial results for amyloidosis treatment By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals Reports Encouraging LINKER-AL2 Trial Results for Lynozyfic® in Systemic AL Amyloidosis - Quiver Quantitative
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron Pharmaceuticals, Inc. Cash Flow – BVL:REGNUS - TradingView
Jim Cramer on Regeneron: “There Could Be Some More Downgrades” - Insider Monkey
Levi & Korsinsky Announces Investigation of Securities Claims Against Regeneron Pharmaceuticals, Inc. (REGN) - GlobeNewswire
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.66%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):